Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.Pharmace ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results